New turkish questionnaire could help scleroderma patients track skin changes
NCT ID NCT07182968
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study aims to translate and test a questionnaire called PASTUL, which helps people with scleroderma assess their own skin thickness. Researchers will enroll 50 Turkish-speaking adults with scleroderma to see if the Turkish version is accurate and reliable. The goal is to give patients a simple way to monitor their condition between doctor visits.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could provide a reliable, patient-friendly tool for Turkish-speaking scleroderma patients to monitor skin thickness at home, potentially improving disease management.
- What could go wrong
- This is a small, early-stage cultural adaptation study (50 participants) focused on questionnaire validation, not a treatment trial. It may not translate into direct clinical benefits or be generalizable beyond the Turkish population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENT PERSPECTIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hacettepe University
RECRUITINGÇankaya, Ankara, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin biopsies unlock new treatments for scleroderma?
- Could a skin patch ease stomach pain in scleroderma?
- Could a painless microneedle pad ease Raynaud's in scleroderma?
- Can a new pill ease the hardening skin of systemic sclerosis?
- A drug after transplant may stop scleroderma from coming back
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.